Five commonly used markers (p53, TTF1, CK7, CK20, and CK34βE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study
- 15 May 2009
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 281 (2) , 317-323
Abstract
Background The choice of appropriate therapeutic plans for primary endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) depends on the tumor’s site of origin. Some panels of antibodies help to distinguish primary ECA from EMA. However, unexpected expressions of those markers often exist, which causes this diagnostic dilemma to be still unresolved. In this study, we investigate five commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34βE12) to evaluate their potential use in distinguishing between these two gynecologic malignancies. Methods A tissue microarray was constructed using paraffin-embedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 ECA and 21 EMA. Utilizing the avidin–biotin (ABC) technique, tissue array sections were immunostained with the five aforementioned commercially available antibodies. Results Immunohistochemical (IHC) expressions of p53, TTF1, CK7, CK20, and CK34βE12 were all nonsignificant (P > 0.05) in frequency differences between the immunostaining results (positive vs. negative) in tumors from both the two primary adenocarcinomas (ECA vs. EMA). Conclusion It is still uncertain which markers or panels would be the most appropriate for making diagnoses; hence, exploration of other useful markers, which make a definitive distinction between ECA and EMA merits further studies. This study, however, uncovered that the five commonly used monoclonal antibodies (p53, TTF1, CK7, CK20, and CK34βE12) are of no beneficial value in distinguishing between primary ECA and EMA.Keywords
This publication has 29 references indexed in Scilit:
- Adding the p16INK4a Marker to the Traditional 3-marker (ER/Vim/CEA) Panel Engenders No Supplemental Benefit in Distinguishing Between Primary Endocervical and Endometrial Adenocarcinomas in a Tissue Microarray StudyInternational Journal of Gynecological Pathology, 2009
- Scoring of p16INK4a immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray studyLaboratory Investigation, 2009
- Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray studyJournal of Translational Medicine, 2009
- TTF-1 Expression in Ovarian and Uterine Epithelial Neoplasia and its Potential Significance, an Immunohistochemical Assessment With Multiple Monoclonal Antibodies and Different Secondary Detection SystemsInternational Journal of Gynecological Pathology, 2009
- Immunoprofile of Adenocarcinomas of the Endometrium, Endocervix, and Ovary With Mucinous DifferentiationApplied Immunohistochemistry & Molecular Morphology, 2009
- Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localizationJournal of Experimental & Clinical Cancer Research, 2008
- Translational medicine: science or wishful thinking?Journal of Translational Medicine, 2008
- Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosisLaboratory Investigation, 2006
- Immunohistochemical Detection of p53 and bcl-2 Proteins in Neoplastic and Non-Neoplastic Endocervical Glandular LesionsInternational Journal of Gynecological Pathology, 1997
- Basic principles of ROC analysisSeminars in Nuclear Medicine, 1978